A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes

Endocrine Journal

Volumn 62, Issue 5, 2015, Pages 449-462

  Yang, Hae Kyung ^a   Min, Kyung Wan ^b   Park, Sung Woo ^c   Chung, Choon Hee ^d   Park, Kyong Soo ^e   Choi, Sung Hee ^f   Song, Ki Ho ^g   Kim, Doo Man ^h   Lee, Moon Kyu ⁱ   Sung, Yeon Ah ^j   Baik, Sei Hyun ^k   Kim, In Joo ^l   Cha, Bong Soo ^m   Park, Jeong Hyun ⁿ   Ahn, Yu Bae ^o   Lee, In Kyu ^p   Yoo, Soon Jib ^q   Kim, Jaetaek ^r   Park, Ie Byung ^s   Park, Tae Sun ^t   Yoon, Kun Ho ^a   more..

^a The Catholic University of Korea   (South Korea)

^b Eulji General Hospital   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Yonsei University Wonju   (South Korea)

^e Seoul National University Hospital   (South Korea)

^f Seoul National University Bundang Hospital   (South Korea)

^g The Catholic University of Korea   (South Korea)

^h Hallym University   (South Korea)

ⁱ Sungkyunkwan University School of Medicine   (South Korea)

^j Ewha Womans University School of Medicine   (South Korea)

^k Korea University College of Medicine   (South Korea)

^l Pusan National University Hospital   (South Korea)

^m Yonsei University College of Medicine   (South Korea)

ⁿ Inje University College of Medicine   (South Korea)

^o The Catholic University of Korea   (South Korea)

^p Kyungpook National University School of Medicine   (South Korea)

^q The Catholic University of Korea   (South Korea)

^r Chung Ang University   (South Korea)

^s Gachon University College of Medicine   (South Korea)

^t Chonbuk National University Medical School   (South Korea)

more..

Author keywords

DPP 4 inhibitor; Glycemic control; Type 2 diabetes

Indexed keywords

ANAGLIPTIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C PEPTIDE; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROINSULIN; TRIACYLGLYCEROL; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; PYRIMIDINE DERIVATIVE;

ADULT; ARTHRALGIA; ARTICLE; BODY MASS; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTRITIS; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT CHANGE; AGED; ANALYSIS; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; MIDDLE AGED;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE; MIDDLE AGED; PLACEBOS; PROINSULIN; PYRIMIDINES;

EID: 84933502701     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ14-0544     Document Type: Article

References (23)

1. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705.
2. Kato N, Oka M, Murase T, Yoshida M, Sakairi M, et al. (2011) Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl} amino)-2-methylpropyl]-2-methyl pyrazolo[1,5-a] pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorg Med Chem 19:7221-7227.
3. Furuta S, Tamura M, Hirooka H, Mizuno Y, Miyoshi M, et al. (2013) Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs. Eur J Drug Metab Pharmacokinet 38:87-96.
4. Nakaya K, Kubota N, Takamoto I, Kubota T, Katsuyama H, et al. (2013) Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet. Metabolism 62:939-951.
5. Ervinna N, Mita T, Yasunari E, Azuma K, Tanaka R, et al. (2013) Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology 154:1260-1270.
6. Furuta S, Smart C, Hackett A, Benning R, Warrington S (2013) Pharmacokinetics and metabolism of [14C] anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans. Xenobiotica 43:432-442.
7. Sunami Y, Yoshika N, Hayashi I, Ishida T (2007) Safety, tolerability, pharmacokinetics and pharmacodynamics of SK-0403, a novel DPP-IV inhibitor, in healthy Japanese subjects. American Diabetes Association 67th Scientific Session Poster 0482-P.
8. Tsubamoto Y, Goto M (2013) Preclinical and clinical aspects of the dipeptidyl peptidase-4 inhibitor anagliptin. Nihon Yakurigaku Zasshi 141: 339-349 (In Japanese).
9. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419.
10. He YL, Wang Y, Bullock JM, Deacon CF, Holst JJ, et al. (2007) Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 47:633-641.
11. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, et al. (2006) Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29:2632-2637.
12. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S (2007) Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 76:132-138.
13. Dejager S, Razac S, Foley JE, Schweizer A (2007) Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 39:218-223.
14. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q (2008) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 31:2315-2317.
15. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, et al. (2009) Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 25:2401-2411.
16. Yang SJ, Min KW, Gupta SK, Park JY, Shivane VK, et al. (2013) A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes. Diabetes Obes Metab 15:410-416.
17. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. (2006) Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a metaregression analysis. Diabetes Care 29:2137-2139.
18. Kaku K (2012) Dose-ranging study of anagliptin in Japanese patients with type 2 diabetes. Jpn Pharmacol Ther 40:973-984.
19. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D (2006) Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 38:423-428.
20. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, et al. (2013) Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 56:696-708.
21. Aso Y, Ozeki N, Terasawa T, Naruse R, Hara K, et al. (2012) Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Transl Res 2012 159:25-31.
22. Barnett A, Allsworth J, Jameson K, Mann R (2007) A review of the effects of antihyperglycemic agents on body weight: the potential of incretin targeted therapies. Current Med Res Opin 23:1493-1507.
23. Scott R, Wu M, Sanchez M, Stein P (2007) Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 61:171-180.